Benzodiazepine use and risk of mortality among patients with schizophrenia: A retrospective longitudinal study

Journal of Clinical Psychiatry

Volumn 77, Issue 5, 2016, Pages 661-667

  Fontanella, Cynthia A ^a   Campo, John V ^a   Phillips, Gary S ^b   Hiance Steelesmith, Danielle L ^a   Sweeney, Helen Anne ^c   Tam, Kwok ^c   Lehrer, Douglas ^c   Klein, Robert ^c   Hurst, Mark ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Ohio Department of Mental Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; CLONAZEPAM; HYPNOTIC AGENT; LORAZEPAM; MOOD STABILIZER; NEUROLEPTIC AGENT; BENZODIAZEPINE DERIVATIVE;

ACCIDENTAL INJURY; ADULT; ARTICLE; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; ICD-9; INTOXICATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHIZOPHRENIA; SUICIDE; ADOLESCENT; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CAUSE OF DEATH; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84973454936     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10271     Document Type: Article

References (35)

1. Haw C, Stubbs J. Benzodiazepines-a necessary evil? a survey of prescribing at a specialist UK psychiatric hospital. J Psychopharmacol. 2007;21(6):645-649. doi:10.17/02698106072386 PubMed.
2. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. Am J Psychiatry. 1991;148(6):714-726. doi:10.176/ajp.148.6.714 PubMed.
3. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006;57(8):1094-1101. doi:10.176/ps.206.57.8.1094 PubMed.
4. Novick D, Bousono M, Suarez D, et al; SOHO Advisory Board. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):972-982. doi:10.1016/j.pnpbp.205.06.03 PubMed.
5. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65(2):151-155. doi:10.408/JCP.v65n0202 PubMed.
6. Wu CS, Lin YJ, Liu SK. Benzodiazepine use among patients with schizophrenia in Taiwan: A nationwide population-based survey. Psychiatr Serv. 2011;62(8):908-914. doi:10.176/ps.62.8.ps62080908 PubMed.
7. Dold M, Li C, Tardy M, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012;11(11):CD006391. PubMed.
8. Brunette MF, Noordsy DL, Xie H, et al. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54(10):1395-1401. doi:10.176/api.ps.54.10.1395 PubMed.
9. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35(suppl): S93-S100. doi:10.1016/S0920-964(98)0161-3 PubMed.
10. Billioti de Gage S, Begaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231. doi:10.136/bmj.e6231 PubMed.
11. Gallacher J, Elwood P, Pickering J, et al. Benzodiazepine use and risk of dementia: Evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2012;66(10):869-873. doi:10.136/jech-201-20314 PubMed.
12. Wu CS, Ting TT, Wang SC, et al. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry. 2011;19(2):151-159. doi:10.1097/JGP.0b013e3181e049ca PubMed.
13. Paterniti S, Dufouil C, Alperovitch A. Longterm benzodiazepine use and cognitive decline in the elderly: The Epidemiology of Vascular Aging Study. J Clin Psychopharmacol. 2002;22(3):285-293. doi:10.1097/04714-202060-09 PubMed.
14. Barker MJ, Greenwood KM, Jackson M, et al. Cognitive effects of long-term benzodiazepine use: A meta-analysis. CNS Drugs. 2004;18(1):37-48. doi:10.2165/023210-20418010-04 PubMed.
15. Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol. 1995;5(3):239-244. doi:10.1016/1047-2797(94)012-7 PubMed.
16. Kao CH, Sun LM, Su KP, et al. Benzodiazepine use possibly increases cancer risk: A population-based retrospective cohort study in Taiwan. J Clin Psychiatry. 2012;73(4): E555-e560. doi:10.408/JCP.1m073 PubMed.
17. Obiora E, Hubbard R, Sanders RD, et al. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: A nested case-control and survival analysis in a population-based cohort. Thorax. 2013;68(2):163-170. doi:10.136/thoraxjnl-2012-202374 PubMed.
18. Tiihonen J, Suokas JT, Suvisaari JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476-483. doi:10.101/archgenpsychiatry.201.1532 PubMed.
19. Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: A population-based nested case-control study. J Clin Psychiatry. 2010;71(2):103-108. doi:10.408/JCP.08m04818yel PubMed.
20. Koroukian SM. Linking the Ohio Cancer Incidence System with Medicare, Medicaid and clinical data from home health care and long term care assessment instruments: paving the way for new research endeavors in geriatric oncology. J Registry Manag. 2008;35(4):156-165. PubMed.
21. Koroukian SM, Beaird H, Duldner JE, et al. Analysis of injury- And violence-related fatalities in the Ohio Medicaid population: identifying opportunities for prevention. J Trauma. 2007;62(4):989-995. doi:10.1097/01.ta.0210359.9816.45 PubMed.
22. Koroukian SM, Cooper GS, Rimm AA. Ability of Medicaid claims data to identify incident cases of breast cancer in the Ohio Medicaid population. Health Serv Res. 2003;38(3):947-960. doi:10.1/1475-673.015 PubMed.
23. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. doi:10.1016/021-9681(87)90171-8 PubMed.
24. Stata Corp. Stata Statistical Software: Release 12, 13. College Station, TX: StataCorp LP; 2013.
25. Lechin F, van der Dijs B, Vitelli-Flores G, et al. Peripheral blood immunological parameters in long-term benzodiazepine users. Clin Neuropharmacol. 1994;17(1):63-72. doi:10.1097/02826-194020-07 PubMed.
26. Kripke DF. Possibility that certain hypnotics might cause cancer in skin. J Sleep Res. 2008;17(3):245-250. doi:10.1/j.1365-2869.208.0685.x PubMed.
27. Mallon L, Broman JE, Hetta J. Is usage of hypnotics associated with mortality? Sleep Med. 2009;10(3):279-286. doi:10.1016/j.slep.208.12.04 PubMed.
28. Sanders RD, Hussell T, Maze M. Sedation & immunomodulation. Crit Care Clin. 2009;25(3):551-570, ix. doi:10.1016/j.c.209.05.01 PubMed.
29. Laschi A, Descotes J, Tachon P, et al. Adverse influence of diazepam upon resistance to Klebsiella pneumoniae infection in mice. Toxicol Lett. 1983;16(3-4):281-284. doi:10.1016/0378-4274(83)9018-1 PubMed.
30. Galdiero F, Bentivoglio C, Nuzzo I, et al. Effects of benzodiazepines on immunodeficiency and resistance in mice. Life Sci. 1995;57(26):2413-2423. doi:10.1016/024-3205(95)0219-0 PubMed.
31. Huemer HP, Lassnig C, Nowotny N, et al. Diazepam leads to enhanced severity of orthopoxvirus infection and immune suppression. Vaccine. 2010;28(38):6152-6158. doi:10.1016/j.vacine.2010.07.032 PubMed.
32. Sanders RD, Myles P, Hubbard R, et al. Benzodiazepines increase mortality from pneumonia: Role of GAB Aergic Signaling, A765. American Society of Anesthesiologists Annual Meeting. October 15-19, 2011; Chicago, IL.
33. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009;166(4):418-426. doi:10.176/api.ajp.208.08070976 PubMed.
34. Allgulander C, Borg S, Vikander B. A 4-6-year follow-up of 50 patients with primary dependence on sedative and hypnotic drugs. Am J Psychiatry. 1984;141(12):1580-1582. doi:10.176/ajp.141.12.1580 PubMed.
35. Wines JD Jr, Saitz R, Horton NJ, et al. Suicidal behavior, drug use and depressive symptoms after detoxification: A 2-year prospective study. Drug Alcohol Depend. 2004;76(suppl):S21-S29. doi:10.1016/j.drugalcdep.204.08.04 PubMed.